644 related articles for article (PubMed ID: 27222041)
21. ADAM Metalloprotease-Released Cancer Biomarkers.
Herrlich P; Herrlich A
Trends Cancer; 2017 Jul; 3(7):482-490. PubMed ID: 28718403
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses.
Wang Q; Li D; Zhang W; Tang B; Li QQ; Li L
Int J Biol Markers; 2011; 26(4):262-73. PubMed ID: 21928244
[TBL] [Abstract][Full Text] [Related]
23. Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies.
Timms JF; Arslan-Low E; Kabir M; Worthington J; Camuzeaux S; Sinclair J; Szaub J; Afrough B; Podust VN; Fourkala EO; Cubizolles M; Kronenberg F; Fung ET; Gentry-Maharaj A; Menon U; Jacobs I
Proteomics Clin Appl; 2014 Dec; 8(11-12):982-93. PubMed ID: 25290619
[TBL] [Abstract][Full Text] [Related]
24. Application of proteomics in ovarian cancer: which sample should be used?
Cadron I; Van Gorp T; Timmerman D; Amant F; Waelkens E; Vergote I
Gynecol Oncol; 2009 Dec; 115(3):497-503. PubMed ID: 19811810
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors.
Zagorianakou N; Stefanou D; Makrydimas G; Zagorianakou P; Briasoulis E; Karavasilis V; Pavlidis N; Agnantis NJ
Histol Histopathol; 2006 Apr; 21(4):341-7. PubMed ID: 16437378
[TBL] [Abstract][Full Text] [Related]
26. Proteomic analyses of serous and endometrioid epithelial ovarian cancers - cases studies - molecular insights of a possible histological etiology of serous ovarian cancer.
Longuespée R; Gagnon H; Boyon C; Strupat K; Dauly C; Kerdraon O; Ighodaro A; Desmons A; Dupuis J; Wisztorski M; Vinatier D; Fournier I; Day R; Salzet M
Proteomics Clin Appl; 2013 Jun; 7(5-6):337-54. PubMed ID: 23589350
[TBL] [Abstract][Full Text] [Related]
27. Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients.
Okła K; Surówka J; Frąszczak K; Czerwonka A; Kaławaj K; Wawruszak A; Kotarski J; Wertel I
Tumour Biol; 2018 Oct; 40(10):1010428318804937. PubMed ID: 30319054
[TBL] [Abstract][Full Text] [Related]
28. Identification and validation of differential plasma proteins levels in epithelial ovarian cancer.
Periyasamy A; Gopisetty G; Subramanium MJ; Velusamy S; Rajkumar T
J Proteomics; 2020 Aug; 226():103893. PubMed ID: 32634479
[TBL] [Abstract][Full Text] [Related]
29. Differential proteomic approach for identification and verification of aberrantly glycosylated proteins in adenocarcinoma lung cancer (ADLC) plasmas by lectin-capturing and targeted mass spectrometry.
Ahn YH; Ji ES; Oh NR; Kim YS; Ko JH; Yoo JS
J Proteomics; 2014 Jun; 106():221-9. PubMed ID: 24780727
[TBL] [Abstract][Full Text] [Related]
30. Proteomic approaches to tumor marker discovery.
Rai AJ; Zhang Z; Rosenzweig J; Shih IeM; Pham T; Fung ET; Sokoll LJ; Chan DW
Arch Pathol Lab Med; 2002 Dec; 126(12):1518-26. PubMed ID: 12456215
[TBL] [Abstract][Full Text] [Related]
31. Proteomic studies of early-stage and advanced ovarian cancer patients.
Wang J; Zhang X; Ge X; Guo H; Xiong G; Zhu Y
Gynecol Oncol; 2008 Oct; 111(1):111-9. PubMed ID: 18703221
[TBL] [Abstract][Full Text] [Related]
32. Protein expression patterns associated with advanced stage ovarian cancer.
Cortesi L; Rossi E; Della Casa L; Barchetti A; Nicoli A; Piana S; Abrate M; La Sala GB; Federico M; Iannone A
Electrophoresis; 2011 Aug; 32(15):1992-2003. PubMed ID: 21728179
[TBL] [Abstract][Full Text] [Related]
33. Identification and validation of salivary proteomic signatures for non-invasive detection of ovarian cancer.
Tajmul M; Parween F; Singh L; Mathur SR; Sharma JB; Kumar S; Sharma DN; Yadav S
Int J Biol Macromol; 2018 Mar; 108():503-514. PubMed ID: 29222021
[TBL] [Abstract][Full Text] [Related]
34. Proximal fluid proteomics for the discovery of digestive cancer biomarkers.
Farina A
Biochim Biophys Acta; 2014 May; 1844(5):988-1002. PubMed ID: 24184935
[TBL] [Abstract][Full Text] [Related]
35. Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer.
Kong F; Nicole White C; Xiao X; Feng Y; Xu C; He D; Zhang Z; Yu Y
Gynecol Oncol; 2006 Feb; 100(2):247-53. PubMed ID: 16229881
[TBL] [Abstract][Full Text] [Related]
36. Translational Research and Plasma Proteomic in Cancer.
Santini AC; Giovane G; Auletta A; Di Carlo A; Fiorelli A; Cito L; Astarita C; Giordano A; Alfano R; Feola A; Di Domenico M
J Cell Biochem; 2016 Apr; 117(4):828-35. PubMed ID: 26479787
[TBL] [Abstract][Full Text] [Related]
37. Identification of ovarian cancer-associated proteins in symptomatic women: A novel method for semi-quantitative plasma proteomics.
Shield-Artin KL; Bailey MJ; Oliva K; Liovic AK; Barker G; Dellios NL; Reisman S; Ayhan M; Rice GE
Proteomics Clin Appl; 2012 Apr; 6(3-4):170-81. PubMed ID: 22532453
[TBL] [Abstract][Full Text] [Related]
38. The serine protease prostasin (PRSS8) is a potential biomarker for early detection of ovarian cancer.
Tamir A; Gangadharan A; Balwani S; Tanaka T; Patel U; Hassan A; Benke S; Agas A; D'Agostino J; Shin D; Yoon S; Goy A; Pecora A; Suh KS
J Ovarian Res; 2016 Mar; 9():20. PubMed ID: 27036110
[TBL] [Abstract][Full Text] [Related]
39. Discovery of potential protein biomarkers of lung adenocarcinoma in bronchoalveolar lavage fluid by SWATH MS data-independent acquisition and targeted data extraction.
Ortea I; Rodríguez-Ariza A; Chicano-Gálvez E; Arenas Vacas MS; Jurado Gámez B
J Proteomics; 2016 Apr; 138():106-14. PubMed ID: 26917472
[TBL] [Abstract][Full Text] [Related]
40. Understanding Ovarian Cancer: iTRAQ-Based Proteomics for Biomarker Discovery.
Swiatly A; Horala A; Matysiak J; Hajduk J; Nowak-Markwitz E; Kokot ZJ
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30065196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
